S
17.89
2.04 (12.87%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | Summit Therapeutics Inc. | 看跌 | 混合的 |
AIStockmoo 评分
0.3
| 分析师共识 | 1.5 |
| 内部交易活动 | NA |
| 价格波动 | 2.0 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | -2.5 |
| 平均 | 0.25 |
|
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Mid Growth |
| 内部持股比例 | 84.32% |
| 机构持股比例 | 13.52% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Polymer Capital Management (Hk) Ltd | 31 Dec 2025 | 1,421,155 |
| Apeiron Capital Ltd | 31 Mar 2026 | 1,309,141 |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合